Filing Details

Accession Number:
0001209191-14-038146
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-05-30 20:00:18
Reporting Period:
2014-05-28
Filing Date:
2014-05-30
Accepted Time:
2014-05-30 20:00:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
858803 Avanir Pharmaceuticals Inc. AVNR Pharmaceutical Preparations (2834) 330314804
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1534986 Md Joao Siffert 20 Enterprise, Suite 200
Aliso Viejo CA 92656
Svp, R&d No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-05-28 13,547 $5.18 230,980 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2014-05-28 10,547 $0.00 10,547 $1.85
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
24,609 2021-12-15 No 4 M Direct
Footnotes
  1. Represents the weighted-average price at which shares were sold within a range between $5.15 and $5.20. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  2. Includes previously reported shares of common stock underlying Restricted Stock Grants granted to the Reporting Person, which are subject to certain vesting conditions. Following the sales reported on this Form 4, the Reporting Person has a total of 185,938 options to purchase shares of common stock that are vested and immediately exercisable and a total of 221,171 options to purchase shares of common stock that have not yet vested. Following the sales reported on this Form 4, the Reporting Person also has 211,045 unvested Restricted Stock Units, of which 43,000 are performance-based Restricted Stock Units.
  3. The option was granted on December 15, 2011 and vests with respect to one-quarter of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares quarterly thereafter over the next three years.
  4. Includes previously reported options granted to the Reporting Person, which are subject to certain vesting conditions.